Partners

EDITOR is consortium of 13 research institutions organised in 3 national hubs, UK, Spain and Italy. We have a common focus on early intervention in monoclonal gammopathies, leukaemia and lymphoma malignancies.

Dr. Jesus San Miguel (Spanish hub coordinator) has championed the notion of cure in MM by treating smoldering myeloma and demonstrating the eradication of MRD must be the aim of therapy.

Dr. Luca Malcovati (Italian hub coordinator) is at the forefront of the genetic basis of MDS and of pre-malignant conditions, including age-related clonal hematopoiesis of indeterminate potenntial (CHIP) and clonal cytopenia of undetermined significance (CCUS).

Dr. Jude Fitzgibbon (UK hub coordinator) was one of the earliest researchers to demonstrate the occurrence of the follicular lymphoma t(14;18)/ IGH-BCL2-rearrangement in healthy individuals and promoted the common progenitor cell (CPC) model to explain the frequent relapsing nature and incurability of this disease.

Spanish Hub

The coordinating institutions are CIMA Universidad de Navarra and Clinica Universidad de Navarra (CUN). The team coordinates the efforts of the Spanish hub and is led by Jesús San Miguel, scientific director of CIMA and Director of Clinical & Translational Medicine at CUN. They will investigate the nature of MRD clones, using high-resolution phenotypic and molecular techniques.

Collaborators:

Jesus San Miguel Izquierdo, Bruno Paiva, Jose Angel Martinez Climent, Felipe Prosper Cardoso, Ane Amundaráin, Xabier Agirre, Teresa Ezponda, Sergio Roa, Juan Jose Garces Latre, Sara Rodríguez, Ainhoa Goñi, Ion Celay

The Clinic Foundation is a non-profit institution based in Barcelona The team from the Foundation involved in the project is led by Iñaki Martín-Subero, and will focus on the bioinformatic analysis of data generated by the project, mining together the generated multi-omics data with other biological and medical data to identify novel molecular signatures and biomarkers, allowing early detection.

Collaborators:

Iñaki Martín-Subero, Vicente Chapaprieta, Stella Charalampopoulou

Lead by Ángel Rubio Díaz-Cordovés, the team from TECNUN is specialised in bioinformatics applied to oncology research. TECNUN is the Engineering College from the University of Navarra.

Collaborators:

Angel Rubio Diaz-Cordoves, Carlos Castilla Ruiz, Juan Angel Ferrer-Bonsoms Hernandez, Marian Gimeno, Fernando Carazo, Francis Planes

The Cancer Research Institute of Salamanca team involved in Editor is specialised in oncohematology, lead by Dr. Marcos González-Díaz, Head of Service at the Universitary Clinic Hospital of Salamanca (HCUS).

Collaborators:

Marcos González, Ramón Garcia Sanz, Norma Gutierrez, María Díez-Campelo, Belen Vidriales, Miguel Alcoceba, Noemí Puig, María García Álvarez

The H12O – CNIO Haematological Malignancies Clinical Research Unit is involved in the project, lead by Dr. Joaquin Martinez-Lopez. The Hospital will provide MRD and molecular analysis in Multiple Myeloma and MDS.

Collaborators:

Joaquin Martinez Lopez, Santiago Barrio, María Linares Gómez, Miguel Gallardo, Juan Manuel Rosa

Italian Hub

The University of Pavia leads the efforts of the Italian hub of Editor. It’s lead by Dr. Mario Cazzola, Professor of Hematology at the Department of Molecular Medicine. The University will research the contribution of the immune system to the transformation from benign to malignant disease states.

Collaborators:

Mario Cazzola, Luca Malcovati, Giovanni Palladini, Giampaolo Merlini, Mario Nuvolone

The university counts with a department of oncology and hematology-oncology, whose efforts are coordinated by Dr. Paolo Corradini, Full Professor of Hematology at the University.

Collaborators:

Paolo Corradini, Cristiana Carniti, Riccardo Betta

Dr. Alessandro Vannucchi from the Department of Experimental and Clinical Medicine leads the contributions of the University of Florence to the project.

Collaborators:

Alessandro Vannucchi, Giada Rotunno

The team at the university of Torino is composed by the group of Dr. Marco Ladetto.

Collaborators:

Marco Ladetto, Simone Ferrero, Elisa Genuardi, Gian Maria Zaccaria

UK Hub

The QMUL team based at Barts Cancer Institute (BCI) in London comprises Professor Fitzgibbon, Dr Okosun and Dr Wang and are focused on the B cell malignancy follicular lymphoma (FL). Professor Jude Fitzgibbon, leads the UK (and FL) hub and is responsible for coordinating research to understand the incurable nature of this indolent malignancy and the population of pre-malignant B cells responsible for seeding new episodes of disease and how these are impacted by the tumour microenvironment.

Collaborators:

Jude Fitzgibbon, Jessica Okosun, Jun Wang, Kevin Roault-Pierre, Eve Coulter, Megan Perrett, Connor Knight

Dr Brian Huntly is leading the efforts from the Cambridge Institute for Medical Research. The institute will be researching follicular lymphoma – generating mouse models for this disease.

Collaborators:

Brian Huntly, Nathalie Sakakini

The Leeds team includes, Dr Roger Owen, Professor Reuben Tooze and Dr Matthew Care and is focused on plasma cell neoplasms, that derive from the terminal effector cells of the B-cell/humoral immune system. The team aims to understand the transition between normal and neoplastic plasma cells, specifically using tools to dissect patterns of gene regulation that identify functional states in normal and neoplastic plasma cells and that reflect interaction of the plasma cell with its microenvironment. Ultimately the goal is to derive tests that identify transitions in plasma cell state in early and minimal disease states.

Collaborators:

Roger Owen, Reuben Tooze, Matthew Care

The team based at the Francis Crick Institute in London is composed of Dr Dinis Calado and Dr Lingling Zhang and is focused on the development of pre-clinical models of follicular lymphoma through genetic manipulation of mice. Once established, these model systems will be used for testing future therapeutics in follicular lymphoma.

Collaborators:

Dinis Calado, Ling-Ling Zheng

Supporters

The Spanish Community of Multiple Myeloma is non for profit association started fby and for persons living with multiple myeloma.

The Amyloidosis Research Consortium is a nonprofit accelerating the development of and access to new and innovative treatments. We are driving the research that will have the greatest impact on length and quality of life for patients.

Facebook community with over 4000 members